🤯 Picked by our AI, this stock rallied more than Nvidia this month, yielding 94% since MarchSee the stock

Immuneering stock target cut to $15 by Needham

EditorAhmed Abdulazez Abdulkadir
Published 03/15/2024, 08:05 AM
© Reuters.
IMRX
-

On Friday, Needham revised its price target for Immuneering Corporation (NASDAQ:IMRX), reducing it to $15.00 from the previous $20.00, while maintaining a Buy rating on the stock. The adjustment follows the release of Phase 1b data for IMM-1-104, Immuneering's drug candidate. The data confirmed the mechanism of action (MOA) at various levels but raised concerns about its standalone efficacy.

IMM-1-104's Phase 1b trial results indicated that the drug was safely administered at the recommended phase 2 dose of 320mg without serious treatment-related adverse events (TRAEs). Furthermore, the drug demonstrated pERK inhibition and prevented new RAS mutations. Despite these positive outcomes, the lack of partial responses (PR) or complete responses (CR) in the trial participants was noted.

The study showed that 53% of patients experienced regression in at least one lesion, and there were instances of stable disease (SD); however, no PRs or CRs were observed. The absence of PRs and CRs could be attributed to several factors, including the small sample size, the advanced stage of cancer in two-thirds of the participants, and a lack of response to prior therapies in 82% of the patients.

The analyst from Needham expressed optimism for the drug's potential efficacy in earlier treatment lines, particularly for NRAS melanoma post-immunotherapy and first-line pancreatic ductal adenocarcinoma (PDAC), based on preclinical data.

Nonetheless, the probability of success (POS) in their model was lowered to reflect the diminished likelihood of significant efficacy as a monotherapy, as suggested by the clinical data to date. This led to the revised price target of $15.00 for Immuneering Corporation's shares.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.